Phanes Therapeutics Unveils Advanced Treatment Strategies
Phanes Therapeutics, Inc., a dedicated clinical-stage biotechnology firm specializing in innovative oncology drug development, is set to present vital findings from its Phase 1/2 clinical study of spevatamig (PT886). This groundbreaking research focuses on the potential of spevatamig in combination with traditional chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (mPDAC). This presentation is scheduled for the prestigious American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, where influential figures in oncology come together to discuss new advances.
Details of the Phase 1/2 Study Presentation
The anticipated presentation will showcase Phanes' clinical trial data from the U.S. multi-center study utilizing spevatamig. The study highlights new opportunities in frontline treatment options for patients battling mPDAC, an aggressive form of pancreatic cancer. Here are some of the key details about the presentation:
Study Title: Phase 1/2 study of spevatamig (PT886) in conjunction with gemcitabine plus nab-paclitaxel (GnP) for mPDAC treatment.
Abstract Number: 709
Session Focus: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date and Time: January 9, 2026, from 11:30 AM to 1 PM (PST)
Lead Author: Anwaar Saeed, MD, of the University of Pittsburgh Medical Center
An Overview of Spevatamig
Spevatamig is an innovative first-in-class bispecific antibody that uniquely targets claudin 18.2 and CD47. Recognizing its potential, the FDA granted orphan drug designation for spevatamig's use in treating pancreatic cancer back in 2022. The drug further achieved Fast Track designation in 2024 for patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma. Collaborating with industry leader Merck, Phanes is now probing the efficacy of combining spevatamig with pembrolizumab, an anti-PD-1 therapy, to enhance patient outcomes.
The TWINPEAK Study
The clinical trial, known as the TWINPEAK study (NCT05482893), explores the safety, tolerability, pharmacokinetics, and initial efficacy of spevatamig. This study not only includes patients with advanced gastric and gastroesophageal junction cancers but also those with pancreatic ductal or biliary tract adenocarcinomas. Additional developments in the TWINPEAK study have begun with a Phase 2 trial currently initiated in China, further expanding the reach and implications of this promising treatment.
About Phanes Therapeutics
Phanes Therapeutics is firmly rooted in advancing oncology through innovative drug research and development practices. Their current portfolio features three essential Phase 1/2 clinical trials, which include the MORNINGSTAR study associated with their cutting-edge monoclonal antibody program, mavrostobart, and the TWINPEAK study featuring spevatamig. Moreover, the SKYBRIDGE study focuses on peluntamig, another promising first-in-class bispecific antibody.
Phanes Therapeutics prides itself on a strategic pipeline built on its proprietary technology platforms: PACbody®, SPECpair®, and ATACCbody®. These platforms facilitate the development of novel bispecific antibodies that exhibit enhanced stability and improved manufacturability while also allowing for reversible modulation of immune activity, showcasing their commitment to pioneering breakthroughs in cancer treatment.
Frequently Asked Questions
What is spevatamig (PT886)?
Spevatamig is a first-in-class bispecific antibody targeting claudin 18.2 and CD47, with promising results in treating pancreatic cancer.
When will the Phase 1/2 study results be presented?
The study results will be showcased at the ASCO Gastrointestinal Cancers Symposium from January 8-10, 2026.
Who is leading the clinical trial?
The lead author of the study is Dr. Anwaar Saeed from the University of Pittsburgh Medical Center.
What is the TWINPEAK study?
The TWINPEAK study evaluates the safety and efficacy of spevatamig in various advanced cancers, including mPDAC.
What other trials is Phanes Therapeutics conducting?
In addition to the TWINPEAK study, Phanes is conducting the MORNINGSTAR and SKYBRIDGE studies, focusing on other innovative treatments.
